Medical Affairs Outsourcing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Medical Affairs Outsourcing Market Report is Segmented by Service (Medical Monitoring, Medical Writing & Publishing, Medical Information, Medical Science Liaisons, Market Access & HEOR Support and More), Industry (Pharma & Biopharma, Medical Device & Diagnostics, Emerging Biotech and More), and Geography (North America, Europe, Asia-Pacific and More). The Market Forecasts are Provided in Terms of Value (USD).

Medical Affairs Outsourcing Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Medical Affairs Outsourcing Market with other markets in Healthcare Industry

Medical Affairs Outsourcing Market Analysis by Mordor Intelligence

The medical affairs outsourcing market size reached USD 2.53 billion in 2025 and is forecast to climb to USD 4.59 billion by 2030, translating into a 12.67% CAGR. Robust demand reflects life-science companies’ decision to focus internal resources on discovery while sourcing regulatory writing, field engagement, and compliance expertise externally. Integrated generative-AI platforms are accelerating document preparation; AstraZeneca already uses large-language-model assistants to support its goal of launching 20 new medicines by 2030. Rising volumes of biologics and specialty-drug trials, ongoing EU MDR surveillance duties, and wider adoption of hybrid and decentralized clinical-trial designs reinforce the preference for flexible, specialist partners. Consolidation among contract development and manufacturing organizations (CDMOs) is adding scale benefits, while regional service hubs in Asia Pacific are winning share through cost and speed advantages. 

Key Report Takeaways

  • By service, Medical Writing & Publishing led with 31.53% of the medical affairs outsourcing market share in 2024; Medical Science Liaisons (MSLs) are projected to expand at a 14.73% CAGR to 2030. 
  • By industry, pharmaceutical and biopharma companies controlled 66.42% of 2024 revenue, whereas emerging biotech is advancing fastest at a 15.43% CAGR through 2030. 
  • By geography, North America held 39.89% of 2024 revenue; Asia Pacific is forecast to record the highest regional CAGR at 15.15% through 2030. 

Segment Analysis

By Service: Leadership of Medical Writing & Publishing with Rapid MSL Growth

Medical Writing & Publishing captured 31.53% of 2024 revenue, making it the largest slice of the medical affairs outsourcing market. High-volume clinical-study reports, risk-management plans, and structured benefit-risk templates anchor consistent demand. Generative-AI text engines reduce drafting time, yet skilled writers remain crucial for data interpretation and regulatory positioning. The segment’s scale also benefits from mandated EU MDR reports and US FDA periodic submissions. 

Medical Science Liaisons generated the fastest expansion, advancing at a 14.73% CAGR to 2030. Growth reflects sponsor emphasis on scientific exchange with healthcare professionals and the need for real-world-evidence insights post-launch. Digital engagement tools allow smaller MSL teams to cover wider territories, yet therapeutic-area depth keeps head-count requirements high. Medical Information, Market Access & HEOR, and Digital/Omnichannel services round out the portfolio, each growing as pricing pressures and omnichannel outreach mature.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Industry: Pharma Dominance Amid Accelerating Emerging-Biotech Demand

Pharmaceutical and biopharma enterprises delivered 66.42% of total 2024 spending in the medical affairs outsourcing market thanks to established operating budgets and global launch pipelines. Their multiyear framework agreements foster integrated programming across writing, safety, and stakeholder engagement, enabling knowledge continuity. 

Emerging biotech shows the most rapid advance with a 15.43% CAGR through 2030 as asset-light start-ups rely on external expertise from pre-IND through commercialization. Medical device and diagnostic companies outsource safety updates and EU MDR documentation, while consumer health and nutraceutical brands engage providers for evidence packages supporting product claims. These adjacent sectors diversify vendor revenue streams and help smooth demand cycles.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America held 39.89% of global 2024 revenue, supported by the largest concentration of R&D budgets, FDA-aligned regulatory timelines, and a mature ecosystem of full-service CROs. Policy initiatives encouraging AI use in drug development further reinforce the region’s appetite for advanced knowledge services.[1]Center for Drug Evaluation and Research Staff, “Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products,” U.S. Food & Drug Administration, fda.gov Canada’s bilingual workforce and Mexico’s near-shore cost advantages complement US capacity, creating a resilient regional hub.

Asia Pacific is forecast to generate the highest growth at a 15.15% CAGR. China and India supply expansive patient pools and competitive costs for clinical operations, while Japan, South Korea, and Australia contribute high-quality regulatory and data-analytics capabilities. Harmonization projects such as ASEAN CTPG reduce submission variance, accelerating multi-country trials. Regional governments also invest in digital-health sandboxes, enticing vendors to base data-science teams locally.

Europe maintains a substantial share despite Brexit-related operational redraws. New device-surveillance rules under EU MDR sustain outsourcing demand for PSUR drafting and vigilance analytics. Initiatives like the European Health Data Space aim to unlock secondary-use datasets, creating longer-term opportunities for evidence-generation specialists.[2]Josefine Westerholm, Christopher Fanelli, Eva von Mühlenen, Michelle Gandolfo, and Julea Lipiz, “Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle,” European Medicines Agency, ema.europa.eu Eastern-European member states offer cost-efficient delivery centers, balancing higher labor costs in Germany and the Netherlands.

Medical Affairs Outsourcing Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The medical affairs outsourcing market remains moderately fragmented, yet top-tier players deepen scale through targeted deals. Novo Holdings’ USD 16.5 billion Catalent acquisition adds fill-finish and gene-therapy capacity, positioning the combined group as an end-to-end partner from manufacturing through post-market medical communications. IQVIA leverages a data-analytics backbone to integrate safety, writing, and field-medical programs, reporting USD 3.83 billion in Q1 2025 revenue with strength in technology solutions.

Syneos Health’s appointment of a new CEO signals renewed focus on operational efficiency and client retention. Parexel’s multi-year agreement with Palantir halves data-delivery timelines in complex trials, underscoring the strategic value of AI-led platforms.[3]Parexel Newsroom Team, “Parexel and Palantir Expand Collaboration to Accelerate Clinical Development,” Parexel Newsroom, newsroom.parexel.com Niche innovators such as Envision Pharma’s 4Sight suite aggregate literature analytics, insight management, and omnichannel planning into unified dashboards, challenging incumbents on speed and transparency.

Strategic priorities center on generating differentiated evidence packages for high-cost therapies, scaling omnichannel HCP engagement, and embedding governance for AI-authored content. Talent acquisition remains a battleground; vendors court experienced MSLs and safety physicians with hybrid work models and upskilling pathways. White-space opportunities persist in digital therapeutics, companion-diagnostic support, and sustainability reporting, areas where few providers yet claim mature offerings.

Medical Affairs Outsourcing Industry Leaders

  1. ICON plc

  2. IQVIA Holdings, Inc.

  3. Syneos Health, Inc.

  4. Thermo Fischer Scientific Inc.

  5. Parexel

  6. *Disclaimer: Major Players sorted in no particular order
Medical Affairs Outsourcing Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: Simplify Healthcare and Atento launched a pilot-first customer-experience program for US payers, using the Xperience1 platform to enhance member and provider engagement.
  • June 2025: hellocare.ai began collaborating with Mayo Clinic on ambient clinical-intelligence solutions targeting reduced hospitalizations.
  • April 2025: HeartBeam and AccurKardia partnered to broaden access to ambulatory ECG monitoring with AI-enabled analytics.

Table of Contents for Medical Affairs Outsourcing Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Cost-Efficiency & Quality Advantages Of Cros
    • 4.2.2 Rising Clinical-Trial Volume & R&D Spend
    • 4.2.3 Pharma Focus On Core Competencies Drives Outsourcing
    • 4.2.4 Expansion Of Biologics & Specialty Drugs
    • 4.2.5 Genai-Enabled Scale-Up Of Medical Writing Productivity
    • 4.2.6 EU-MDR Post-Market Surveillance Needs In Medtech
  • 4.3 Market Restraints
    • 4.3.1 Shortage & Turnover Of Skilled Medical-Affairs Talent
    • 4.3.2 Cross-Border Data-Privacy / Compliance Complexity
    • 4.3.3 Regulatory Uncertainty Over AI-Generated Content
    • 4.3.4 Vendor Consolidation Limiting Supplier Opportunities
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Service
    • 5.1.1 Medical Monitoring
    • 5.1.2 Medical Writing & Publishing
    • 5.1.3 Medical Information
    • 5.1.4 Medical Science Liaisons (MSLs)
    • 5.1.5 Market Access & HEOR Support
    • 5.1.6 Digital / Omnichannel Medical Affairs
    • 5.1.7 Other Niche Services
  • 5.2 By Industry
    • 5.2.1 Pharma & Biopharma
    • 5.2.2 Medical Device & Diagnostics
    • 5.2.3 Emerging Biotech
    • 5.2.4 Consumer Health & Nutraceuticals
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 IQVIA Holdings Inc.
    • 6.3.2 ICON plc
    • 6.3.3 Syneos Health Inc.
    • 6.3.4 Parexel International Corp.
    • 6.3.5 Thermo Fisher Scientific (PPD)
    • 6.3.6 Indegene Ltd.
    • 6.3.7 Accenture (Life Sciences)
    • 6.3.8 Ashfield Engage
    • 6.3.9 The Medical Affairs Company (TMAC)
    • 6.3.10 SGS S.A.
    • 6.3.11 Wuxi Clinical Development
    • 6.3.12 EVERSANA
    • 6.3.13 Charles River Laboratories
    • 6.3.14 Medpace Holdings
    • 6.3.15 Labcorp Drug Development (Covance)
    • 6.3.16 OPEN Health
    • 6.3.17 Fishawack Health
    • 6.3.18 Certara
    • 6.3.19 PharmaLex
    • 6.3.20 Zeincro Group
    • 6.3.21 Clinigen Group

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Medical Affairs Outsourcing Market Report Scope

As per the scope of the report, medical affairs outsourcing refers to a process that enables patients, healthcare professionals, and government bodies to gain deep insights into healthcare policies, operations, and patient data. The Medical Affairs Outsourcing Market is Segmented By Services (Medical Monitoring, Medical Writing & Publishing, Medical Information, Medical Science Liaisons, and Others), Industry (Medical Devices and Pharma and biopharmaceuticals), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.

By Service Medical Monitoring
Medical Writing & Publishing
Medical Information
Medical Science Liaisons (MSLs)
Market Access & HEOR Support
Digital / Omnichannel Medical Affairs
Other Niche Services
By Industry Pharma & Biopharma
Medical Device & Diagnostics
Emerging Biotech
Consumer Health & Nutraceuticals
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Service
Medical Monitoring
Medical Writing & Publishing
Medical Information
Medical Science Liaisons (MSLs)
Market Access & HEOR Support
Digital / Omnichannel Medical Affairs
Other Niche Services
By Industry
Pharma & Biopharma
Medical Device & Diagnostics
Emerging Biotech
Consumer Health & Nutraceuticals
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current size of the medical affairs outsourcing market?

The market is valued at USD 2.53 billion in 2025.

2. What annual growth rate will the medical affairs outsourcing market register through 2030?

The forecast calls for a 12.67% CAGR, lifting revenue to USD 4.59 billion by 2030.

3. Which service segment holds the largest share of market revenue?

Medical Writing & Publishing leads with 31.53% of 2024 revenue, driven by regulatory-document volume and scientific-communication needs.

4. Which region will grow the fastest over the next five years?

Asia Pacific is projected to expand at a 15.15% CAGR, supported by rising clinical-trial activity and regulatory harmonization.

5. What is the most significant restraint affecting market expansion?

A global shortage and high turnover of skilled medical-affairs talent, estimated at a 35% deficit by 2030, is exerting a −1.8% drag on forecast CAGR.

6. How is generative AI influencing medical affairs outsourcing demand?

GenAI tools shorten document-preparation cycles and add an estimated +1.4% to CAGR by boosting medical-writing productivity and freeing experts for higher-value analysis.

Page last updated on: July 1, 2025

Medical Affairs Outsourcing Market Report Snapshots